相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining
Rafal Wierzbicki et al.
INVESTIGATIONAL NEW DRUGS (2011)
Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab
Li-Chen Yen et al.
ANNALS OF SURGERY (2010)
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
Jolien Tol et al.
EUROPEAN JOURNAL OF CANCER (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
Mario E. Lacouture et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab
Carla Campanella et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
Mario E. Lacouture et al.
SUPPORTIVE CARE IN CANCER (2010)
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
S. Lorenzen et al.
ANNALS OF ONCOLOGY (2009)
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
Russell J. Schilder et al.
GYNECOLOGIC ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway
Antonio Russo et al.
ONCOLOGY (2009)
Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab - an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis
Xiao Su et al.
ONCOLOGY (2009)
Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147
Aminah Jatoi et al.
ONCOLOGY (2009)
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study
L. D. Locati et al.
ORAL ONCOLOGY (2009)
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer:: a phase Ib/II study of the AIO GI Group
D. Arnold et al.
ANNALS OF ONCOLOGY (2008)
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
M. Borner et al.
ANNALS OF ONCOLOGY (2008)
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
R. Rosell et al.
ANNALS OF ONCOLOGY (2008)
EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F. Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer
Charles A. Butts et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption
Alon Scope et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers
J. Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results
Susan L. Boone et al.
ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management
Thomas J. Lynch et al.
ONCOLOGIST (2007)
Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer
Nasser Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mechanisms of cutaneous toxicities to EGFR inhibitors
Mario E. Lacouture
NATURE REVIEWS CANCER (2006)
Epidermal growth factor receptor targeting in cancer
John Mendelsohn et al.
SEMINARS IN ONCOLOGY (2006)
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
G Folprecht et al.
ANNALS OF ONCOLOGY (2006)
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer
F Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cutaneous adverse effects with HER1/EGFR-targeted agents:: Is there a silver lining?
R Peréz-Soler et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pharmacokinetic profile of cetuximab (Erbitux™) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma
C Delbaldo et al.
EUROPEAN JOURNAL OF CANCER (2005)
HER1/EGFR inhibitor-associated rash:: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
R Pérez-Soler et al.
ONCOLOGIST (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial
HQ Xiong et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors - A new paradigm for cancer therapy
RS Herbst et al.
CANCER (2002)
分享论文
